EDITORIAL article
Front. Nutr.
Sec. Nutrition and Microbes
This article is part of the Research TopicFrom Nutrients, Food Matrices, Bioactive Compounds, to Microbiota: Exploring the Path to Optimal Human Health - Congress Farm to Fork: Our Food, Our Health, Our FutureView all 7 articles
Editorial: From Nutrients, Food Matrices, Bioactive Compounds, to Microbiota: Exploring the Path to Optimal Human Health - Congress Farm to Fork: Our Food, Our Health, Our Future
Provisionally accepted- 1Centro de Apoio Tecnológico Agro Alimentar (CATAA), Castelo Branco, Portugal
- 2Centre for Functional Ecology, Associate Laboratory TERRA, Department of Life Sciences, University of Coimbra, Coimbra, Portugal
- 3Institute of Environmental Biotechnology, Graz University of Technology, Graz, Austria
- 4Nutrition & Metabolism, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Lisboa, Portugal
- 5CHRC, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Lisboa, Portugal
- 6Sport Physical Activity and Health Research & Innovation Center (SPRINT) - Polytechnic University of Castelo Branco, Castelo Branco, Portugal
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Inspired by the Farm to Fork: Our Food, Our Health, Our Future Congress (Castelo Branco, Portugal), this Research Topic examines the final farm-to-fork stage, where nutritional quality, bioactive compounds, edible microbiota and food matrices intersect to shape human health; the papers were not presented at the Congress but reflect its themes.The studies gathered in this Research Topic tell a coherent story: diet acts both through content and structure. Not simply over grams of a nutrient, but through the way food matrices and microbial communities meet and modulate host physiology. Read together, these papers advance four main practical ideas. First, microstructure guides which microbes and metabolites prevail. Second, immune and metabolic function can shift even when community composition seems unchanged, so outcomes that capture function deserve equal footing with taxonomic profiles. Third, intact matrices shape risk and benefit, calling for matrix-aware guidance aligned with Farm-to-Fork.Two contributions on fibres and resistant starch (RS) make the "structure matters" point concrete. Tang et al. test an RS3 from Canna edulis (CE) and show that simulated digestion increases crystallinity and surface roughness, explaining enzyme resistance and readiness for colonic fermentation. In faecal cultures, the post-digestion material lowered pH, increased short-chain fatty acids, expanded Bifidobacterium and suppressed Escherichia-Shigella, whereas fructo-oligosaccharide acidified more deeply and reduced diversity. CE thus offers a credible functional-food candidate and a clear example of microstructure steering fermentation.Chong and co-workers take the next step with upcycled fruit fibres and shows clear, source-specific responses. In a short, randomised intervention, green banana (GBP) and pineapple (PFP) powders (both enriched in insoluble fibre) were well tolerated, improved bowel regularity, increased beneficial taxa and boosted microbial functions (including SCFA and vitamin-linked pathways). Effects were source-specific and subgroupdependent, yet both interventions suppressed Escherichia-Shigella and raised Bifidobacterium without loss of diversity. These results make a practical case for circular, food-grade fibres that shift fermentation toward health-relevant metabolites, though longer, diet-controlled trials across different population groups are needed to test durability and clinical impact.Fermentation emerges here as a design tool rather than a culinary afterthought. Zhu et al. show that a practical Levilactobacillus brevis process can deliver a GABA-enriched under standard dairy conditions -no new equipment, sensory quality intact, live cultures maintained, and GABA stable during chilled storage. Mixed co-fermentation with Streptococcus thermophilus further raises GABA while keeping acidity in the commercial range. In effect, fermented dairy is positioned as a carrier for neuroactive metabolites relevant to blood pressure, stress and sleep -areas where modest, food-based effects matter. The next step is clear: dose-response trials that track clinical endpoints and confirm that bioactivity persists across shelf life. More broadly, it shows how strain, process and matrix can be tuned together to deliver function, not just a label claim.In the same vein, and continuing to harness microorganisms as cell factories for potentially functional bioactive food ingredients, Yu and colleagues screened Lacticaseibacillus paracasei ZFM54 for strong exopolysaccharide (EPS) production and optimised its fermentation. EPS effectively reduced Helicobacter pylori colonisation to the epithelial AGS cells, recovering cell morphology, and alleviated gastritis in infected mice, partly restoring gastric microbiota structure, and shifted cytokine expression toward a less inflammatory profile. Noteworthy, as antibiotic resistance rises, a structuredefined biopolymer with antimicrobial and immunomodulatory actions is notable and these results provide a basis to explore food applications (e.g., fermented dairy), pending human safety and pharmacokinetic data.Safety is treated with the same emphasis on function. Fischer and colleagues exposed a simplified gut community co-cultured with immune cells to common chemical mixtures (bisphenols, PFAS). Immune-modulating capacity changed despite little movement in alpha-or beta-diversity, challenging the use of composition alone as a proxy for health. Preclinical screens and human studies should therefore register functional readouts (e.g. immune phenotypes, SCFA and bile-acid panels, barrier measures) alongside taxonomy, and validate in vitro against in vivo outcomes.The matrix argument is illustrated in the narrative review by Eugénio et al. which revisit cheese, a food with a long cultural history and a complex food matrix. Synthesising recent observational and interventional evidence, they conclude that cheese, particularly in its intact matrix, does not appear linked to adverse cardiometabolic outcomes and may confer protection. Plausible mechanisms include calcium-mediated lipid handling, microbial peptides with ACE-inhibitory activity, SCFA production, polar lipids and an active microbiota. Methodologically, trials must control fat and salt while varying microstructure; matrix-matched, longer randomised trials are needed to show causality and inform new matrix-based dietary guidelines.What, then, should the field do differently? First, put function on par with composition. Register immune and metabolite endpoints up front in protocols, not as exploratory afterthoughts. Second, describe the materials properly (e.g. for fibres that means reporting crystallinity, branching, particle size, etc). Without these, reproducibility and synthesis suffer. Third, lengthen and power trials appropriately. Many diet studies are too short to capture adaptation; according to the literature, 8-12 weeks seems to a sensible minimum for fibre and resistant starch, with dose-response built in, background diet recorded or controlled, and analyses stratified by age, BMI and baseline microbiome. Fourth, test matrices head-to-head. For example, in cheese studies hold fat and salt constant and vary microstructure to isolate matrix effects. Finally, align health impact with sustainability by clinically evaluating ingredients and communicating structure and function clearly to consumers.It is also worth noting the limits of what is currently known. Short interventions and modest doses may underestimate effect sizes or fail to show durability. In vitro models that highlight functional shifts need in vivo confirmation, although they provide an ethical and standardisable first filter. Heterogeneity in medication use, lifestyle and baseline microbiota will continue to modulate response; that is an argument for a priori stratification. And composition-only readouts can create misplaced confidence; functional outcomes help prevent that.Why does this agenda matter for Farm-to-Fork? It connects foods people actually eat, ingredients that use resources better, and outcomes that change population-level risk. Banana and pineapple fibres illustrate clinically relevant upcycling; GABA yoghurt shows an everyday matrix carrying a specific bioactive; EPS work suggests a non-antibiotic adjunct in gastric infection; and the cheese review reminds us matrices can gate risk as much as nutrients. None of these advances rest on a single super-ingredient; they rest on structure and context.In sum, the papers in this Topic support a practical shift in nutrition science: from counting to understanding, from lists of components to the ways in which matrices and microbes interact with the host. By pre-registering functional outcomes, giving structural features the same attention as nutrient amounts, and adopting longer, stratified trials, researchers can judge foods on performance rather than composition alone. The result benefits health and sustainability and fits the Farm-to-Fork agenda.
Keywords: Food matrices, bioactive compounds, Fibre, microbiota, sustainable foods
Received: 03 Nov 2025; Accepted: 10 Nov 2025.
Copyright: © 2025 Brandão, Wicaksono, Faria, Coelho and Espírito Santo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Inês Brandão, inesbrandao@cataa.pt
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.